BETTER-B: BETter TreatmEnts for Refractory Breathlessness

Mirtazapine to alleviate severe breathlessness in patients with COPD or ILD: an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial (BETTER-B) (2024)
Journal Article
Higginson, I. J., Brown, S. T., Oluyase, A. O., May, P., Maddocks, M., Costantini, M., Bajwah, S., Normand, C., Bausewein, C., Simon, S. T., Ryan, K., Currow, D. C., Johnson, M., Hart, S. P., Mather, H., Krajnik, M., Tanzi, S., Ghirotto, L., Bolton, C., Janowiak, P., …Brown, J. M. (2024). Mirtazapine to alleviate severe breathlessness in patients with COPD or ILD: an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial (BETTER-B). Lancet, 12(10), 763-774. https://doi.org/10.1016/S2213-2600%2824%2900187-5

Background
Breathlessness frequently becomes severe among people with respiratory disease. Mirtazapine, a widely used antidepressant, showed promise. We determined the effectiveness of mirtazapine to alleviate severe persisting breathlessness.
Meth... Read More about Mirtazapine to alleviate severe breathlessness in patients with COPD or ILD: an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial (BETTER-B).